Literaturverzeichnis

Für Sie recherchiert

Literaturverzeichnis

Als kompetenter Partner der Allergologen und als Unternehmen mit hoher wissenschaftlicher Kompetenz haben wir den Anspruch, Sie regelmäßig und umfassend über die relevanten Erkenntnisse rund um Publikationen zu unseren Produkten zu informieren. Hier finden Sie - nach Erscheinungsjahr sortiert - eine Übersicht mit Publikationen zu ALK-Präparaten.

 

2016: 4 Einträge
  • Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J, Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 2016; 137 (2): 444-451
  • Horn A, Zeuner H, Wolf H, Schnitker J, Wüstenberg E. Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study. Clin Drug Investig 2016, DOI 10.1007/s40261-016-0388-9
  • Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma – A Randomized Clinical Trial. JAMA. 2016; 315 (16): 1715-1725.
  • Reiber R, Keller M, Keller W, Wolf H, Schnitker J, Wüstenberg E. Tolerability of the SQ‑standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non‑interventional observational study. Clin Transl Allergy 2016;6:9
2015: 3 Einträge
  • Nolte H, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, Kaur A, Zieglmayer P, Zieglmayer R, Lemell P, Horak F, Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 2015; 135(6):1494-501
  • Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H, Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112: 146-153
  • Tabar AI, González Delgado P, Sánchez Hernández C, Basagaña Torrento M, Moreno Benítez F, Arina M, Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy. J Investig Allergol Clin Immunol 2015;25(1):40-46.
2014: 3 Einträge
  • Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z, Andersen JS, Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy 2014; 69 (5): 617-623
  • Kleine-Tebbe J, Walmar M, Bitsch-Jensen K, Decot E, Pfaar O, de Rojas DH, Rodriguez F, Negative clinical results from a randomised, double-blind, placebocontrolled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response. Clin Drug Investig 2014; 34: 577-586
  • Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW, Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014 Sep; 134 (3): 568-575
2013: 3 Einträge
  • Gronke Ch, Wolf H, Schnitker J, Wüstenberg E, Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet is well tolerated in Children, Adolescents and Adults in Real Life Application – A Non-Interventional Observational Study. J Allergy Ther 2013; 4: 146
  • Hylander T, Latif L, Petersson-Westin U, Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013; 131: 412-420
  • Nelson H, Blaiss M, Nolte H, Würtz SØ, Andersen JS, Durham SR, Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013 Feb; 68 (2): 252-255
2012: 8 Einträge
  • Armentia A, Carballada F, Carretero P, de Paz S, Lobera T, Marcos C, Martínez JC, Rodríguez I, Soto T, Venturini M, de la Torre F, Postmarketing study for assessment of tolerability of a grass allergen immunotherapy tablet (GRAZAX) in patients with rhinitis or rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2012; 22 (7): 485-490
  • Durham SR, Emminger W, Kapp A, de Monchy JGR, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R, SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129: 717-725
  • Lou W, Wang C, Wang Y, Han D, Zhang L, Enhancement of the Frequency and Function of IL-10-Secreting Type I T Regulatory Cells after 1 Year of Cluster Allergen-Specific Immunotherapy. Int Arch Allergy Immunol 2012; 159: 391-398
  • Möbs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Würtzen PA, Hertl M, Pfützner W, Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130: 1108-1116
  • Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E, Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 2012; 67 (5): 630-637
  • Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E, Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin Ther 2012; 34: 2072-2081
  • Shamji MH, Ljørring C, Francis JN, A Calderon M, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Würtzen PA, Durham SR, Functional rather than immunoreactive levels of IgG(4) correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012 Feb; 67 (2): 217-226
  • Wessel F, Chartier A, Meunier J-P, Magnan A, Safety and Tolerability of an SQ-Standardized Grass Allergy Immunotherapy Tablet (GRAZAX) in a Real-Life Setting for Three Consecutive Seasons – The GRAAL Trial. Clin Drug Investig 2012 Jul 1; 32 (7): 451-463
2011: 10 Einträge
  • Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP, Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adole scents. J Allergy Clin Immunol 2011; 127: 64-71
  • Blumberga G, Groes L, Dahl R, SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy 2011 Feb; 66 (2): 178-185
    Durham SR (on behalf of the GT-08 investigators), Sustainedeffects of grass pollen AIT. Allergy 2011; 66 (Suppl. 95): 50-52
  • James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham SR, Long-term tolerance after allergen immunotherapy is accom panied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011 Feb; 127 (2): 509-516
  • Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I, A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011 Oct; 128 (4): 808-815
  • Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI, Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127: 72-80
  • Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W, Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: A phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther 2011; 33 (7): 828-840
  • Schlegel D, Wolf H, Schnitker J, Wüstenberg E, Immunotherapy with a fast updosed hypoallergenic SCIT formulation: A retrospective study on tolerability in children and adolescents. Allergy 2011; 66 (Suppl 94): 209
  • Valovirta E, Effect of AIT in children including potential to prevent the development of asthma. Allergy 2011; 66 (Suppl. 95): 53-54
  • Valovirta E, Herland Berstad AK, de Blic J, Bufe A, Eng P, Halken S, Ojeda P, Roberts G, Tommerup L, Varga EM, Winnergard I, Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen-Induced Allergic Rhinoconjunctivitis, Clin Ther 2011; 33 (10): 1537-1546
  • Wolf H, Becker F, Becker S, Schnitker J, Wüstenberg E, Immuntherapie mit einem schnell aufdosierten hypoallergenen SCIT-Präparat: Verträglichkeit der Aufdosierung und der Erhaltungstherapie während der Routine-Anwendung. Allergo J 2011; 20: 44-45
2010: 4 Einträge
  • Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JGR, Rak S, Scadding GK, Andesen JS, Riis B, Dahl R, Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138 33.
  • Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB, Clinical efficacy and immunological mecha nisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010 Jun; 40 (6): 922-932
  • Frølund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, Dahl R, Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality
    of life. Allergy 2010 Jun 1; 65 (6): 753-757
  • Martínez-Cócera C, Sastre J, Cimarra M, Quirce S, Fernández-Rivas M, Enríquez-Matas A, Rodríguez-Álvarez M, Martín S, Immunotherapy with a phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol 2010; Vol. 20(1): 13-19
2009: 4 Einträge
  • Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weißhaar C, Kaiser F, Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123: 167-173
  • Chen ZG, Li M, Chen YF, Ji JZ, Li YT, Chen W, Chen FH, Chen H, Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children. Chin Med J (Engl) 2009 May 20; 122 (10): 1157-1161
  • Jansen A, Andersen KF, Brüning H, Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: An a priori subgroup analysis. Clinical Therapeutics 2009; 31 (2):321-327
  • Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J, Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009; 148 (2): 161-169
2008: 5 Einträge
  • Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Riis B, Grønager PM, Durham SR, Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121: 512-518
  • Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ, Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008 May; 121 (5): 1120-1125
  • Henmar H, Lund G, Lund L, Petersen A, Würtzen PA, Allergenicity, immunogenicity and doserelationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008 Sep; 153 (3): 316-323
  • Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A, Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec. 2008; 70 (3): 144-150
  • Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H, A double-blind placebocontrolled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008 Aug; 38 (8): 1290-1301
2007: 5 Einträge

 

  • Durham SR, Riis B, Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62: 954-957
  • Ibañez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B, Bufe A, Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007; 18: 516-522
  • Jacobsen L, Niggemann B, Dreborg S et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62 (8): 943-948
  • Powell RJ, Frew AJ, Corrigan CJ, Durham SR, Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007; 62 (11): 1335-1338
  • Rak S, Yang WH, Pedersen MR, Durham SR, Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinconjunctivitis: A double-blind, randomised study. Quality of Life Research 2007 Mar;16(2):191-201.
2006: 15 Einträge
  • Alessandrini AE, Berra D, Rizzini FL et al., Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann Allergy Asthma Immunol 2006; 97 (1): 92-97
  • Blumberga G, Groes L, Haugaard L, Dahl R, Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006; 61 (7): 843-848
  • Calderon M, Essendrop M, Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006; Vol. 16 (6): 338-344
  • Dahl R, Stender A, Rak S, Specific immunotherapy with SQ standardized grass allegen tablets in asthma tics with rhinoconjunctivitis. Allergy 2006; 61: 185-190
  • Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR, Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440
  • Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S, Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809
  • Frew AJ, Powell RJ, Corrigan CJ, Durham SR, Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117 (2): 319-325
  • Kleine-Tebbe J, Ribel M, Herold DA, Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61: 181-184
  • Malling HJ, Lund L, Ipsen H, Poulsen L, Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006; Vol. 16 (3): 162-168
  • Niggemann B, Jacobsen L, Dreborg S et al., Five-year follow-up on the PAT study: specific immunotherapy and long- term prevention of asthma in children. Allergy 2006; 61 (7): 855-859
  • Quercia O, Emiliani F, Pecora S, Burastero SE, Stefanini GF, Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 2006; 27 (2): 151-158
  • Roberts G, Hurley C, Turcanu V, Lack G, Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117 (2): 263-268
  • Wang H, Lin X, Hao C et al., A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61 (2): 191-197
  • Werfel T, Breuer K, Rueff F et al., Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randmized, dose-response study. Allergy 2006; 61 (2): 202-205
  • Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H, Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006; 36 (3): 254-260
2005: 5 Einträge
  • Bødtger U, Ejrnaes AM, Hummelshoj L, Jacobi HH, Poulsen LK, Svenson M, Is immunotherapy- induced birch-pollen-specific IgG4 a marker for decreased allergen-specific sensitivity? Int Arch Allergy Immunol 2005 Apr; 136 (4): 340-346
  • Haye R, Dosen LK, Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998. Clin Mol Allergy 2005 Aug; 19: 3-12
  • Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR, IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005 Jul; 116 (1): 73-79
  • Rabe U, Wolf H, Bockmeyer M, Schnitker J, Verträglichkeit und Therapieeffekt der spezifischen Immuntherapie mit einem standardisierten Alternaria alternata - Allergenpräparat. Allergo J 2005; 14: 125-133
  • Tabar AI, Echechipía S, García BE, Olaguibel JM, Lizaso MT, Gómez B, Aldunate MT, Martin S, Marcotegui F, Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005 Jul; 116 (1): 109-118
2004: 10 Einträge
  • Arvidsson MB, Lowhagen O, Rak S, Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59 (1): 74-80
  • Bolhaar ST, Tiemessen MM, Zuidmeer L, van Leeuwen A, Hoffmann-Sommergruber K, Bruijnzeel-Koomen CA, Taams LS, Knol EF, van Hoffen E, van Ree R, Knulst AC, Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004 May; 34 (5): 761-769
  • Bucher X, Pichler WJ, Dahinden CA, Helbling A, Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004 Dec; 59 (12): 1272-1276
  • Cadario G, Marengo F, Ranghino E et al., Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Investig Allergol Clin Immunol 2004; 14 (2): 127-133
  • Crimi N, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C, Lisitano N, Polosa R, A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int 2004 Apr-Jun; 19 (2): 98-108
  • Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR, Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004 Mar 1; 172 (5): 3252-3259
  • Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B, Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed prepartions. Allergy 2004; 59 (6): 589-595
  • Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO, Increased expression of allergen- induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004 Mar; 34 (3): 413-419
  • Van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Würtzen PA, A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004 Mar; 34 (3): 420-428
  • Wilcock LK, Francis JN, Durham SR, Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004 Sep; 34 (9): 1373-1378
2003: 4 Einträge
  • Kopp MV, Mayatepek E, Engels E, Brauburger J, Riedinger F, Ihorst G, Wahn U, Kuehr J, Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). Pediatr Allergy Immunol 2003 Oct; 14 (5): 401-404
  • Oude Elberink JN, Dubois AE, Quality of life in insect venom allergic patients. Curr Opin Allergy Clin Immunol 2003; 3 (4): 287-293
  • Polosa R, Li Gotti F, Mangano G, Mastruzzo C, Pistorio MP, Crimi N, Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin Exp Allergy 2003 Jul; 33 (7): 873-881
  • Varney VA, Tabbah K, Mavroleon G, Frew AJ, Usefulness of specific immunotherapy in patients with severe peren nial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33 (8): 1076-1082
2002: 9 Einträge
  • Arvidsson MB, Lowhagen O, Rak S, Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109 (5): 777-783
  • Bødtger U, Poulsen LK, Jacobi HH, Malling HJ, The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebocontrolled study. Allergy 2002; 57 (4): 297-305
  • Fernandez-Tavora L, Rico P, Martin S, Clinical experience with specific immunotherapy to horse dander. J Investig Allergol Clin Immunol 2002; 12 (1): 29-33
  • Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U, Efficacy of combination treatment with anti-IgE plus specific immunotherapy in poly-sensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002 Feb; 109 (2): 274-280
  • Möller C, Dreborg S, Ferdousi HA et al., Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109 (2): 251-256
  • Oude Elberink JN, De Monchy JG, Van Der HS, Guyatt GH, Dubois AE, Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110 (1): 174-182
  • Sturm G, Kranke B, Rudolph C, Aberer W, Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002; 110 (6): 928-933
  • Wolf H et al., The LQC-study: quality of life and compliance with specific immunotherapy against grass and rye allergens after 3 years of treatment. Allergy 2002; 57 (73): 77-78
2001: 7 Einträge
  • Gabrielsson S, Söderlund A, Paulie S, van der Pouw Kraan TC, Troye-Blomberg M, Rak S, Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 2001 Apr; 56 (4): 293-300
  • Pajno GB, Barberio G, De LF, Morabito L, Parmiani S, Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31 (9): 1392-1397
  • Pichler CE, Helbling A, Pichler WJ, Three years of specific immunotherapy with house-dustmite extracts in patients with rhinitis and asthma: significant improvement of allergenspecific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56 (4): 301-306
  • Poli F, Longo G, Parmiani S, The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study. Allergol Immunopathol (Madr) 2001; 29 (5): 191-196
  • Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P, A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108 (6): 921-928
  • Rueff F, Wenderoth A, Przybilla B, Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108 (6): 1027-1032
  • Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR, Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107 (1): 87-93
2000: 7 Einträge
  • Akmanlar N, Altintas DU, Güneser KS, Yilmaz M, Bingöl G, Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr) 2000 Jul-Aug; 28 (4): 213-218
  • Bergmann KC, Wolf H, Petermann F und die LQC Studiengruppe, Lebensqualität und Compliance von Patienten bei der spezifischen Immuntherapie mit Gräser- und Roggenallergenen (LQC-Studie), Allergo J 2000; 9: 480-488
  • Brehler R, Wolf H, Kutting B, Schnitker J, Luger T, Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1231-1235
  • Mellerup MT, Hahn GW, Poulsen LK, Malling H, Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30 (10): 1423-1429
  • Mosbech H, Muller U, Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Euro pean Academy of Allergology and Clinical Immunology. Allergy 2000; 55 (11): 1005-1010
  • Winther L, Malling HJ, Moseholm L, Mosbech H, Allergen-specific immunotherapy in birch and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy 2000 Sep; 55 (9): 818-826
  • Winther L, Malling HJ, Mosbech H, Allergen-specific immunotherapy in birch- and grasspollen- allergic rhinitis. II. Side-effects. Allergy 2000 Sep; 55 (9): 827-835
1999: 2 Einträge
  • Durham SR, Walker SM, Varga EM et al., Long-term clinical efficacy of grass-pollen immun therapy. N Engl J Med 1999; 341 (7): 468-475 > Hedlin G, Wille S, Browaldh L et al., Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999; 103 (4):609-614
1998: 1 Eintrag
  • Movérare R, Rak S, Elfman L, Allergen-specific increase in interleukin (IL)-4 and IL-5 secreton from peripheral blood mononuclear cells during birch-pollen immunotherapy. Allergy 1998 Mar; 53 (3): 275-281
1997: 8 Einträge
  • Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O, Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997 Sep; 27 (9): 1007- 1015
  • Håkansson L, Heinrich C, Rak S, Venge P, Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997 Apr; 99 (4): 551-562
  • Haugaard L, Dahl R, Sparholt S, Jacobsen L, A Dose-Response Study of Immunotherapy in Asthmatics: 6-Year Follow-up. Allergy 1997; 52 (37): 162
  • Ipsen H, Lowenstein H, Basic features of crossreactivity in tree and grass pollen allergy. Clin Rev Allergy Immunol 1997; 15 (4): 389-396
  • Jacobsen L, Nuchel PB, Wihl JA, Lowenstein H, Ipsen H, Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52 (9): 914-920
  • Olsen OT, Larsen KR, Jacobsan L, Svendsen UG, A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52 (8): 853-859
  • Pichler CE, Marquardsen A, Sparholt S et al., Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997; 52 (3): 274-283
  • Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27 (8): 860-867
1996: 3 Einträge
  • Dolz I, Martínez-Cócera C, Bartolome JM, Cimarra M, A double-blind, placebocontrolled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51 (7): 489-500
  • Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA, Grass pollen immuno therapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996 Jun; 97 (6): 1356-1365
  • Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ, Antihistamine premedication in specific cluster immuno therapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996 Jun; 97 (6): 1207-1213
1995: 3 Einträge
  • Hedlin G, Heilborn H, Lilja G et al., Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96 (6 Pt 1): 879-885
  • Olsen OT, Frolund L, Heinig J, Jacobsen L, Svendsen UG, A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa. Allergol Immunopathol (Madr) 1995; 23 (2): 73-78
  • Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR, Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50 (5): 405-413
1993: 3 Einträge
  • Haugaard L, Dahl R, Jacobsen L, A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91 (3): 709-722
  • Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR, Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutane ous responses. J Clin Invest 1993 Aug; 92 (2): 644-651
  • Wyss M, Scheitlin T, Stadler BM, Wuthrich B, Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a propective study over 3 years. Allergy 1993; 48 (2): 81-86
1992: 1 Eintrag
  • Sparholt SH, Olsen OT, Schou C, The allergen specific B-cell response during immunotherapy. Clin Exp Allergy 1992 Jun; 22 (6): 648-653
1991: 4 Einträge
  • Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB, Immunotherapy and allergic inflammation. Clin Exp Allergy 1991 Jan; 21 (1): 206-210
  • Hedlin G, Graff-Lonnevig V, Heilborn H et al., Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87 (5): 955-964
  • Rak S, Björnson A, Håkanson L, Sörenson S, Venge P, The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991 Dec; 88 (6): 878-888
  • Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR, Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302 (6771): 265-269
1990: 2 Einträge
  • Boye NP, Salo OP, Hyldebrandt N, Wihl JA, Bevan A, Harris RI, Lovely JR, Immunotherapy of tree pollen allergy with a modified alginate conjugated birch pollen extract compared to an aluminium adsorbed extract. Allergy 1990 May; 45 (4): 241-248
  • Rak S, Håkanson L, Venge P, Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990 Nov; 86 (5): 706-713
1989: 3 Einträge
  • Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Ostergaard PA, Immunotherapy with dog and cat extracts in children. Allergy 1989; 44 (5): 330-335
  • Collet M, Urbanek R, Allergenimmunotherapie mit einem immunchemisch charakterisierten Gräserpollen-Extrakt Änderung der Sensibilisierungsparameter im Verlauf. Klin. Pädiatr 1989; 201: 183-188
  • Lilja G, Sundin B, Graff-Lonnevig V et al., Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 1989; 83 (1): 37-44
    Svendsen UG et al., The effect of immunotherapy on specific and concomitant mugwort pollen allergy in a double blind study. Allergologie 1989; 12 (9): 17-22
1988: 7 Einträge
  • Ipsen H, Schwartz B, Wihl JA et al., Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy. Allergy 1988; 43 (5): 370-377
  • Mosbech H, Osterballe O, Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43 (7): 523-529
  • Petersen BN, Janniche H, Munch EP et al., Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43 (5): 353-362
  • Rak S, Löwhagen O, Venge P, The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988 Sep; 82 (3 Pt 1): 470-480
  • Van MT, Marsh DG, Adkinson NF et al., Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82 (6): 1055-1068
  • Wahn U, Schweter C, Lind P, Løwenstein H, Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988 Sep; 82 (3 Pt 1): 360-370
  • Wihl JA, Ipsen H, Petersen BN, Munch EP, Janniche H, Lowenstein H, Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43 (5): 363-369
1986: 5 Einträge
  • Hedlin G, Graff-Lonnevig V, Heilborn H et al., Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986; 77 (3): 488-496
  • Løwenstein H, Graff-Lonnevig V, Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Sundin B, Immunotherapy with cat- and dog-dander extracts. III. Allergen-specific immunoglobulin responses in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986 Mar; 77 (3): 497-505
  • Mosbech H, Malling HJ, Biering I et al., Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986; 41 (2): 95-103
  • Sundin B, Lilja G, Graff-Lonnevig V et al., Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77 (3): 478-487
  • Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L, Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986; 57 (3): 173-179
1985: 1 Eintrag
  • Malling HJ, Djurup R, Sondergaard I, Weeke B, Clustered immunotherapy with Yellow Jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy 1985; 40 (5): 373-383
1984: 1 Eintrag
  • Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L, Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984; 53 (1): 85-88
1983: 1 Eintrag
  • Osterballe O, Ipsen H, Weeke B, Løwenstein H, Specific IgE response toward allergenic molecules during perennial hyposensitization: a three-year prospective double-blind study. J Allergy Clin Immunol 1983 Jan; 71 (1 Pt 1): 40-46
1982: 6 Einträge
  • Osterballe O, Egeskjold EM, Johansen AS, Skov P, Anti-IgG antibodies during immunotherapy with purified grass pollen extracts. Allergy 1982 Apr; 37 (3): 209-216
  • Osterballe O, Løwenstein H, Malling HJ, Petersen BN, Weeke B, Is is possible to predict the clinical effect of hyposensitization? Int Arch Allergy Appl Immunol 1982; 68 (3): 286-288
  • Osterballe O, Løwenstein H, Norn S, Prahl P, Skov P, Skov PS, Weeke B, Immunotherapy with grass pollen major allergens. Immunological results from a prospective 3-year double blind study. Allergy 1982 Oct; 37 (7): 491-501
  • Osterballe O, Immunotherapy with grass pollen major allergens. Allergy 1982; 37 (6): 379-388
  • Osterballe O, Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen. Allergy 1982 Apr; 37 (3): 169-177
  • Osterballe O, Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982 Nov; 37 (8): 553-562
1981: 1 Eintrag
  • Osterballe O, Løwenstein H, Prahl P, Skov P, Weeke B, Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vitro variables, season i. Allergy 1981 Apr; 36 (3): 183-199
Letzte Aktualisierung: 2017.02.23